Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShares IssuedShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Cash from Operations (2016 - 2025)

Regen BioPharma (RGBPP) has disclosed Cash from Operations for 12 consecutive years, with 197941.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations fell 198.2% to 197941.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 515153.0, a 21.42% increase, with the full-year FY2025 number at 383591.0, up 48.96% from a year prior.
  • Cash from Operations was 197941.0 for Q4 2025 at Regen BioPharma, down from 160005.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 10463.0 in Q4 2022 to a low of 1067017.0 in Q3 2021.
  • A 5-year average of 170781.26 and a median of 118818.0 in 2022 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: soared 96.25% in 2022, then tumbled 1451.52% in 2023.
  • Regen BioPharma's Cash from Operations stood at 279135.0 in 2021, then skyrocketed by 96.25% to 10463.0 in 2022, then crashed by 1451.52% to 162336.0 in 2023, then surged by 59.11% to 66379.0 in 2024, then plummeted by 198.2% to 197941.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBPP's Cash from Operations are 197941.0 (Q4 2025), 160005.0 (Q3 2025), and 55977.0 (Q2 2025).